Biostage Files for FDA Orphan Drug Designation for Cellspan™ Esophageal Implant
Categories
Biostage, Inc. (Nasdaq: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced it has submitted an application with the U.S. Food and Drug Administration seeking orphan drug designation for its Cellspan Esophageal Implants.
http://www.stockhouse.com/news/press-releases/2016/06/29/biostage-files-for-fda-orphan-drug-designation-for-cellspan-esophageal-implant